Melanoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{CMG}} | __NOTOC__ | ||
{{CMG}} {{AE}} {{YD}} | |||
{{Melanoma}} | {{Melanoma}} | ||
Line 6: | Line 7: | ||
==Pathophysiology== | ==Pathophysiology== | ||
===Molecular Pathogensis=== | ===Molecular Pathogensis=== | ||
*The development of melanoma | *The development of melanoma begins with the disruption of nevus growth control.<ref name="pmid16822996">{{cite journal| author=Miller AJ, Mihm MC| title=Melanoma. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 1 | pages= 51-65 | pmid=16822996 | doi=10.1056/NEJMra052166 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16822996 }} </ref> | ||
*The progression to melanoma involves the of serine-threonine kinases ofthe ERK-MAPK pathway (mitogen-activated protein kinase) pathway following mutation of either the ''N-RAS'' or ''BRAF'' oncogene. | *The progression to melanoma involves the of serine-threonine kinases ofthe ERK-MAPK pathway (mitogen-activated protein kinase) pathway following mutation of either the ''N-RAS'' or ''BRAF'' oncogene. | ||
*It is thought the the progression to melanoma follows the two-hit hypothesis, where activation of the oncogene alone does not lead to the development of melanoma, and additional mutations, such as loss-of-function mutation of ''P53'' tumor-suppressor gene (or less commonly ''CDKN2A'' or ''PTEN'' in familial cases) is required for the development of melanoma.<ref name="pmid16822996">{{cite journal| author=Miller AJ, Mihm MC| title=Melanoma. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 1 | pages= 51-65 | pmid=16822996 | doi=10.1056/NEJMra052166 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16822996 }} </ref> | *It is thought the the progression to melanoma follows the two-hit hypothesis, where activation of the oncogene alone does not lead to the development of melanoma, and additional mutations, such as loss-of-function mutation of ''P53'' tumor-suppressor gene (or less commonly ''CDKN2A'' or ''PTEN'' in familial cases) is required for the development of melanoma.<ref name="pmid16822996">{{cite journal| author=Miller AJ, Mihm MC| title=Melanoma. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 1 | pages= 51-65 | pmid=16822996 | doi=10.1056/NEJMra052166 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16822996 }} </ref> |
Revision as of 22:05, 21 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.
Melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Melanoma pathophysiology On the Web |
American Roentgen Ray Society Images of Melanoma pathophysiology |
Risk calculators and risk factors for Melanoma pathophysiology |
Overview
Pathophysiology
Molecular Pathogensis
- The development of melanoma begins with the disruption of nevus growth control.[1]
- The progression to melanoma involves the of serine-threonine kinases ofthe ERK-MAPK pathway (mitogen-activated protein kinase) pathway following mutation of either the N-RAS or BRAF oncogene.
- It is thought the the progression to melanoma follows the two-hit hypothesis, where activation of the oncogene alone does not lead to the development of melanoma, and additional mutations, such as loss-of-function mutation of P53 tumor-suppressor gene (or less commonly CDKN2A or PTEN in familial cases) is required for the development of melanoma.[1]
- The development of melanoma may arise de-novo or from pre-existing nevi. In both cases, mutations result in dysplasia and cytologic atypia that predispose to the malignant pontential of the cells.
- As more genes are mutated and the tumor grows, changes include the overexpression of N-cadherin, αVβ3 integrin, MMP-2, MSH, cAMP, and survivin, and the loss of E-cadherin and TRMP1 proteins.[1]
- The following genes are involved in the pathogenesis of melanoma:[1]
- Tumor-suppressor genes:
- p53
- CDK2NA
- PTEN
- RB
- ARF
- Proto-oncogenes:
- N-RAS
- BRAF
- CCND1
Genetics
Pathology
Common Subclasses | Features on Gross Pathology | Features on Histopathological Microscopic Analysis |
Superficial spreading melanoma |
|
|
Nodular melanoma |
|
|
Acral lentiginous melanoma |
|
|
Lentigo maligna melanoma |
|
|
Non-cutaneous melanoma |
|
|
Dermoplastic/Spindle cell melanoma |
|
|
Nevoid melanoma |
|
|
Spitzoid melanocytic neoplasm |
|
|
Angiotropic melanoma |
|
|
Blue nevus-like melanoma |
|
|
Composite melanoma |
Features of more than one subtype on gross pathology |
|
References
- ↑ 1.0 1.1 1.2 1.3 Miller AJ, Mihm MC (2006). "Melanoma". N Engl J Med. 355 (1): 51–65. doi:10.1056/NEJMra052166. PMID 16822996.